

Carvedilol (Coreg®)

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2019. ACOG Practice Bulletin No. 203 Summary: Chronic Hypertension in Pregnancy. Obstet Gynecol; 133(1): 215-219.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf; 20:138-145.
- Kubota K, et al. 2023. Alpha/beta- and beta-blocker exposure in pregnancy and the risk of neonatal hypoglycemia and small for gestational age. Circ J; 87: 569-577.
- Lennestål R, et al. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol; 65(6): 615-625.
- McCowan LM, et al. 1996. Perinatal morbidity in chronic hypertension. Br J Obstet Gynecol; 103:123-129.
- Ray JG, et al. 2001. McMaster outcome study of hypertension in pregnancy. Early Hum Dev; 64:129-143.
- Rey E, Couturier A. 1994. The prognosis of pregnancy in women with chronic hypertension. Am J Obst Gynecol; 181:410-416.
- Sibál BM, et al. 2000. Preterm delivery in women with pregestational diabetes or chronic hypertension relative to women with uncomplicated pregnancies. The National Institute of Child Health and Human Development – Fetal Medicine Units Network. Am J Obst Gynecol; 183:1520-1524.
- Tanaka K, et al. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J; 80: 2221-2226.
- Waylis Therapeutics LLC. 2025. Coreg Product Label. Available at: <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm>. Accessed 12 June 2026.
- Yakoob MY, et al. 2013. The risk of congenital malformations associated with exposures to beta-blockers early in pregnancy: A meta-analysis. Hypertension; 62(2): 375-381.

Dúvidas? Ligue para 866.626.6847 | Envie mensagem de texto para 855.999.3525 | Envie e-mail ou acesso o Chat no endereço MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 de junho de 2026.

Carvedilol (Coreg®)

Selected References:

- American College of Obstetricians and Gynecologists (ACOG). 2026. COVID-19 FAQs for obstetrician-gynecologists, obstetrics. <https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics>. Accessed June 2026
- Anderson PO. 2022. COVID-19 drugs and breastfeeding update. Breastfeed Med; 17:377-9.
- Chourasia P, et al. 2023. Paxlovid (nirmatrelvir and ritonavir) use in pregnant and lactating woman: Current evidence and practice guidelines-a scoping review. Vaccines (Basel); 11:107.
- Chuang MT, et al. 2024. Transplacental passage of nirmatrelvir in pregnant women with COVID-19. Int J Gynaecol Obstet; 164(1):351-353.
- Corbett AH, al. 2014. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: Results of the BAN Study. Antivir Ther; 19:587-595.
- Dai J, et al. 2024. Low Nirmatrelvir and Ritonavir Exposure through Breastmilk: Analyzing Milk Concentrations and Infant Risk. Clin Pharmacol Ther; 116(5):1217-1221.
- Gandhi M, et al. 2013. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr; 63:578-584.
- Garneau WM, et al. 2022. Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir for acute SARS-CoV-2 infection. JAMA Netw Open; 5(11):e2244141.
- Lin CY, et al. 2023. Nirmatrelvir-ritonavir (Paxlovid) for mild coronavirus disease 2019 (COVID-19) in pregnancy and lactation. Obstet Gynecol; 141:957-60.
- Lin CW, et al. 2023. Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic. J Infect Public Health; 16(12):1942-1946.
- Loza A, et al. 2022. Short-term pregnancy outcomes after nirmatrelvir-ritonavir treatment for mild-to-moderate coronavirus disease 2019 (COVID-19). Obstet Gynecol; 140(3):447-449.
- Palombi L, et al. 2012. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther; 17:1511-1519.

- Pfizer Laboratories Div Pfizer Inc. Last updated October 18, 2023. Paxlovid drug label. Source: National Library of Medicine. Available at <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a99d6d6-fd9e-45bb-b1bf-48c7f761232a>. Accessed June 2026.
- Ramírez-Ramírez A, et al. 2018. Simultaneous quantification of four antiretroviral drugs in breast milk samples from HIV-positive women by an ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method. PLoS One; 13:e0191236.
- Rezk NL, et al. 2008. Studies on antiretroviral drug concentrations in breast milk: Validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit; 30:611-9.
- Yang H, et al. 2025. Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy. Matern Child Health J; 29(5):599-603.

Dúvidas? Ligue para 866.626.6847 | Envie mensagem de texto para 855.999.3525 | Envie e-mail ou acesso o Chat no endereço MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 de junho de 2026.

Carvedilol (Coreg®)

Selected References:

- Campbell LS, et al. 2025. Balancing Mental Health and Breastfeeding: Evaluating the Transfer of Lurasidone Into Human Milk. J Clin Psychiatry; 86(4):25m15955.
- Cohen LS, et al. 2023. Reproductive safety of lurasidone and quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. J Womens Health (Larchmt); 32(4):452-462.

- Cruz MP. 2011. Lurasidone HCl (Latuda), an oral, once-daily atypical antipsychotic agent for the treatment of patients with schizophrenia. P & T: a peer-reviewed journal for formulary management; 36(8):489-492.
- Damkier, P & Videbech, P. 2018. The safety of second-generation antipsychotics during pregnancy: A clinically focused review. CNS Drugs; 32:351-366.
- FDA. 2011. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Previously retrieved from <http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm>.
- Greenberg WM & Citrome L. 2017. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet; 56:493-503.
- Kantrowitz JT, Citrome L. 2012. Lurasidone for schizophrenia: what's different? Expert Rev Neurother; 12(3):265-73.
- Keightley P, et al. 2020. Lurasidone in lactation: A case study with laboratory and clinical outcomes. Aust N Z J Psychiatry; 54:1035-1036.
- Kernizan N, et al. 2024. Mood stabilizers for treatment of bipolar disorder in pregnancy and impact on neonatal outcomes. Bipolar Disord; 26(8):779-784.
- Kernizan N, et al. 2025. Prescribing Patterns for the Treatment of Bipolar Disorder in Pregnancy: A Retrospective Cohort Study. J Clin Med; 14(5):1638.
- Luo Z, et al. 2025. The safety analysis of lurasidone based on the real-world data of FAERS database. Expert Opin Drug Saf; 1-11.
- Montiel C, et al. 2022. Perinatal use of lurasidone for the treatment of bipolar disorder. Exp Clin Psychopharmacol; 30(2):249-252.
- Sumitomo Pharma America, Inc. (Last updated 2025). Latuda drug label. Source: National Library of Medicine. Available at <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8>.
- Terrana N, et al. 2015. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: A systematic review and meta-analysis. Journal of Clinical Psychopharmacology; 35(5):559-565.
- Viguera AC, et al. 2022. Breastfeeding practices among women taking second-generation antipsychotics: Findings from the National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health; 25:511-6.
- Wang E, et al. 2025. Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes. CNS Drugs; 39(1):1-22.

Dúvidas? Ligue para 866.626.6847 | Envie mensagem de texto para 855.999.3525 | Envie e-mail ou acesso o Chat no endereço MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 de junho de 2026.

Carvedilol (Coreg®)

Selected References:

- Barr M Jr, Cohen MM Jr. 1991. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. *Teratology*; 44:485-495.
- Bhatt-Mehta V, Deluga KS. 1993. Fetal exposure to lisinopril: neonatal manifestations and management. *Pharmacotherapy*;13(5): 515-518.
- Burrows RF, Burrows EA. 1998. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. *Aust N Z J Obstet Gynaecol*; 38(3):306-311.
- Chugh J, Dai J, Datta P, Krutsch K. 2025. Investigating the transfer of lisinopril into human milk: a quantitative analysis. *J CardiovascPharmacol*;85(1):4-87.
- Cooper WO, et al. 2006. Major congenital malformations after first-trimester exposure to ACE inhibitors. *N Engl J Med*; 354(23): 2443-2451.
- Diav-Citrin O, et al. 2011. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. *Reprod Toxicol*; 31(4):540-545.
- Filler G, et al. 2003. Early dialysis in a neonate with intrauterine lisinopril exposure. *Arch Dis Child Fetal Neonatal Ed*;88(2):F154-156.
- Friedman JM. 2006. ACE inhibitors and congenital anomalies. *NEnglJ Med*, 354:2498-2500.
- Karthikeyan VJ, et al. 2011. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. *J Hypertens*, 29(2):396-399.
- Lennestall R, et al. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. *Eur J Clin Pharmacol*, 65(6):615-625.
- Lip GYH, et al. 1997. Angiotensin-converting-enzyme inhibitors in early pregnancy. *Lancet*, 350:1446-1447.
- Merck Sharp and Dohme Corp. 2018. Prinivil product label. Moretti ME, et al. 2012. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. *Obstet Gynecol Int*; 2012:658310.
- Moretti ME, et al. 2012. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. *Obstet Gynecol Int*; 2012:658310.
- National Collaborating Centre for Women's and Children's Health (UK). 2011. Hypertension in Pregnancy. Appendix O. Safety of commonly used antihypertensive drugs during breastfeeding. NICE ClinicalGuidelines, No. 107. London: RCOG Press.
- Polifka JE.2012.Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. *Birth Defects Res (Part A)*, 94:576-598.
- Pryde PG, et al. 1993. Angiotensin-converting enzyme inhibitor fetopathy. *J Am Soc Nephrol*,3:1575-1582.
- Rosa F, Bosco L. 1991. Infant renal failure with maternal ACE inhibition. *Am JObstetGynecol*, 161(1 Part 2):273

(abstract).

- Tomlinson AJ, et al. 2000. Malignant primary hypertension in pregnancy treated with lisinopril. *Ann Pharmacother*,34(2):180-182.
- U.S. Food and Drug Administration (FDA).1992.Upgraded warning on the use of ACE inhibitors during pregnancy.
- Yip SK, et al.1998. Exposure to angiotensin-converting enzyme inhibitors duringfirsttrimester: is it safe to fetus? *Acta Obstet Gynecol Scand*; 77:570-571.

Dúvidas? Ligue para 866.626.6847 | Envie mensagem de texto para 855.999.3525 | Envie e-mail ou acesso o Chat no endereço [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 de junho de 2026.

Carvedilol (Coreg®)

Selected References:

- Atmaca M, Kuloglu M, Tezcan E, Canatan H, Gecici,O. 2002. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. *Arch Med Res* 33:562-5.
- Beumont PJ, Gelder MG, Friesen HG, et al. 1974. The effects of phenothiazine on endocrine function: I Patients with inappropriate lactation and amenorrhoea. *Br J Psychiatry*. 124:413-9.
- Crawford AM, Beasley CM Jr, Tollefson GD. 1997. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. *Schizophr Res*. 26:41-54.
- Cho H, et al. 2025. Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns. *J Affect Disord*. 373:495-504.
- Diav-Citrin O, Shechtman S, Ornoy S, et al. 2005. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. *Journal of Clinical Psychiatry* 66:317-322.
- Dieulangard P et al. 1966. Sur un cas d'ectro-phocomelie peutetre d'origine medicamenteuse. *Bull Fed Gynecol Obstet* 18:85-87.
- Fiore L, Scapagnini U, Canonico PL. 1987. Effect of dihydroergocryptine and dihydroergocristine on cyclic AMP

- accumulation and prolactin release in vitro: Evidence for a dopaminomimetic action. *Horm Res.* 25:171-177.
- Kallen et al. 2013 The use of central nervous system active drugs during pregnancy. *Pharmaceuticals* 6(10):1221-1286.
 - Kopelman AE et al. 1975. Limb malformations following maternal use of haloperidol. *J Am Med Assoc* 231:62-64.
 - Langer G, Puhlinger W. 1980. Haloperidol and droperidol treatment in schizophrenics. Clinical application of the "prolactin-model". *Acta Psychiatr Belg.* 80:574-83.
 - Maguire GA. 2002. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. *J Clin Psychiatry.* 63(suppl 4):56-62.
 - Straub L, Hernández-Díaz S, Bateman BT, et al. 2022. Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders: A National Birth Cohort Study. *JAMA Intern Med.* 182(5):522-533.
 - Straub L, et al. 2026. Congenital malformation risk following prenatal antipsychotic exposure: a systematic safety surveillance approach. *BMJ Ment Health.* 29(1):e302270.
 - Turkington RW. 1972. Prolactin secretion in patients treated with various drugs: Phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. *Arch Intern Med.* 130:349-354.
 - Turkington RW. 1972. Serum prolactin levels in patients with gynecomastia. *J Clin Endocrinol Metab.* 34:62-66.
 - Uguz F. 2016. Breastfed infants exposed to combined antipsychotics: Two case reports. *Am J Ther.* 23:e1962-e1964
 - Uguz F. 2019. Adverse events in a breastfed infant exposed to risperidone and haloperidol. *Breastfeed Med.* 14:683-684.
 - Uguz F. 2021. A new safety scoring system for the use of psychotropic drugs during lactation. *Am J Ther.* 28:e118-e126
 - Van Waes A, Van de Velde E. 1969. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. *J Clin Pharmacol* 9:224-227.
 - Wang, E., et al.. 2026. Correction: Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: A systematic review and network meta-analysis of congenital malformations and prenatal outcomes. *CNS Drugs* 40, 841-863.
 - Whalley LJ, Blain PG, Prime JK. 1981. Haloperidol secreted in breast milk. *Br Med J (Clin Res Ed).* 282:1746-1747.
 - Yoshida K, Smith B, Craggs M, et al. 1997. Investigation of pharmacokinetics and possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. *J Affect Disord.* 43:225-237.
 - Yoshida K, Smith B, Craggs M, et al. 1998. Neuroleptic drugs in breast-milk: A study of pharmacokinetics and of possible adverse effects in breast-fed infants. *Psychol Med.* 28:81-91.

Dúvidas? Ligue para 866.626.6847 | Envie mensagem de texto para 855.999.3525 | Envie e-mail ou acesso o Chat no endereço MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 de junho de 2026.